文献速递骨质疏松与代谢性骨病

中国HIV感染者启动抗逆转录病毒治疗后骨密度的纵向变化

Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy.
PubMed 文献 · Osteoporos Int · 2020-08-15

该回顾性研究分析了北京某三级医院HIV门诊2007年3月至2016年5月启动抗逆转录病毒治疗且基线与48和/或96周有双能X线吸收测定法检测的136例患者,发现含替诺福韦二吡呋酯(TDF)方案组脊柱和髋部骨密度下降幅度大于非TDF组,并报告了HIV诊断时长和病毒载量与髋部及股骨颈骨密度降低相关。

要点

  • 含TDF方案组较非TDF组脊柱骨密度从基线至48周下降更多(-2.94% vs -0.74%)。
  • 含TDF方案组较非TDF组髋部骨密度从基线至96周下降更多(-4.37% vs -2.34%)。
  • HIV诊断时长每增加1年与髋部骨密度降低相关(RR 0.97,95%CI 0.95-0.99)。

核心结论

  • 这是中国首次报告HIV感染者在启动含TDF抗逆转录病毒治疗后骨密度变化及相关风险因素的研究。
  • 研究结果为该地区HIV感染者的长期临床管理提供了重要知识。

研究设计与样本

  • 回顾性分析北京某大型三级医院HIV门诊2007年3月至2016年5月的患者。
  • 纳入在启动抗逆转录病毒治疗前及启动后48和/或96周接受双能X线吸收测定法检测的患者,共136例。

主要发现

  • 共纳入136例患者,平均年龄36.0±10.6岁,超过90%为男性且为汉族。
  • 含TDF组较非TDF组脊柱骨密度从基线至48周下降更多(-2.94% vs -0.74%)。
  • 含TDF组较非TDF组髋部骨密度从基线至96周下降更多(-4.37% vs -2.34%)。
  • HIV诊断时长每增加1年与96周内髋部骨密度降低相关(RR 0.97,95%CI 0.95-0.99)。
  • 病毒载量持续检测不到与96周内髋部骨密度降低相关(RR 0.96,95%CI 0.94-0.99)。

关键数值与推荐

  • HIV诊断时长每增加1年与96周内股骨颈骨密度降低相关(RR 0.97,95%CI 0.95-0.99)。
  • 病毒载量持续检测不到与96周内股骨颈骨密度降低相关(RR 0.97,95%CI 0.95-0.998)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This is the first study to report changes in BMD and related risk factors among Chinese patients with HIV after initiation of tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy. Greater bone mineral density (BMD) loss was observed in patients treated with TDF, compared to those on non-TDF-containing regimens. Our findings provide important knowledge regarding the risk factors in the long-term clinical management of patients with HIV in China. INTRODUCTION: Persons living with HIV (PLWH) are at increased risk for osteoporosis and fracture. Tenofovir disoproxil fumarate (TDF) has been associated with higher rates of bone mineral density (BMD) loss, osteoporosis, and fracture. Few studies have studied the impact among PLWH in Asia. METHODS: We analyzed retrospectively patients from the outpatient HIV clinic of a large tertiary hospital in Beijing, China, from March 2007 to May 2016. Patients who had dual-energy X-ray absorptiometry testing prior to antiretroviral initiation and at 48 and/or 96 weeks after initiation were included in this analysis. RESULTS: A total of 136 patients were included (mean age 36.0 ± 10.6 years) and over 90% participants were male and Han Chinese ethnicity. We observed greater declines in BMD at the spine from baseline to week 48 (-2.94% vs. -0.74%) and at the hip from baseline to week 96 (-4.37% vs. -2.34%) in the TDF group compared with the non-TDF group. With regard to HIV-specific parameters, longer duration since HIV diagnosis and undetectable viral load over time were associated with lower BMD at the hip [relative risk (RR) 0.97, 95% confidence index (CI) (0.95, 0.99) per 1 year increase and RR 0.96, 95%CI (0.94, 0.99), respectively] and femoral neck [RR 0.97, 95%CI (0.95, 0.99) per 1 year increase and RR 0.97, 95%CI (0.95, 0.998), respectively] over 96 weeks. CONCLUSIONS: This is the first study to report changes in BMD among PLWH after initiation of TDF-based antiretroviral therapy in China. Our findings provide important knowledge for the long-term clinical management of PLWH from this region.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Guo F, Song X, Li Y, et al. Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy. Osteoporos Int. 2020. PMID: 32803316. doi:10.1007/s00198-020-05584-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。